Lower Manufacturing Costs Integral To Perrigo 2003 Strategy, CEO Says
This article was originally published in The Tan Sheet
One of Perrigo's primary goals for the coming fiscal year will be to reduce its manufacturing expenditures and improve its "low-cost supplier position.
You may also be interested in...
Perrigo plans to increase R&D spending in the second half of FY 2001 pending a favorable FDA follow-up manufacturing audit of the firm's Allegan, Mich. facility, President & CEO David Gibbons told analysts during a conference call Jan. 23.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning